Therapeutics strategies for the management of urinary tract infection in children;Stratégies thérapeutiques dans les infections urinaires du nourrisson et de l'enfant

Archives de Pediatrie

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Launay, E ^a   Bingen, E ^b   Cohen, R ^c,d  

^a Hopital Mere Enfant CHU de Nantes   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d Association clinique et therapeutique infantile du Val de Marne ACTIV   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFIXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CHILD; CHILD CARE; CYSTITIS; DRUG DISTRIBUTION; ESCHERICHIA COLI INFECTION; HUMAN; NONHUMAN; URINARY TRACT INFECTION;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PYELONEPHRITIS; URINARY TRACT INFECTIONS;

EID: 84869768713     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/S0929-693X(12)71283-6     Document Type: Article

References (48)

1. Beetz R., Westenfelder M. Antimicrobial therapy of urinary tract infections in children. Int J Antimicrob Agents 2011, 38(Suppl):42-50.
2. Montini G., Tullus K., Hewitt I. Febrile urinary tract infections in children. N Engl J Med 2011, 365:239-250.
3. AFSSAPS. Diagnostic et antibiotherapie des infections urinaires bacteriennes communautaires du nourrisson et de l'enfant. 2007. Disponible en ligne: http://www.infectiologie.com/site/medias/_documents/consensus/afssaps-inf-urinaires-enfant-reco.pdf.
4. Gauthier M, Brunet S, Garel L, et al. Lignes directrices de prise en charge des infections urinaires du CHU Sainte Justine, Montréal, Canada. Mises à jour 2012. Disponible en ligne : Dernier accès le 16 mai 2012. http://www.urgencehsj.ca/librairies/sfv/telecharger.php%3Ffichier=1148.
5. Newman T.B. The new American Academy of Pediatrics urinary tract infection guideline. Pediatrics 2011, 128:572-575.
6. The National Institute for Health and Clinical Excellence (NICE). Urinary tract infection in children: Diagnosis, treatment and long-term management. Disponible en ligne: http://publications.nice.org.uk/urinary-tract-infection-in-children-cg54.2007.
7. Rodriguez-Bano J., Navarro M.D., Romero L., et al. Bacteremia due to extended-spectrum beta - lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006, 43:1407-1414.
8. Rodriguez-Bano J., Picon E., Gijon P., et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extendedspectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010, 48:1726-1731.
9. Cohen R., Copin C., Bingen E. Réflexions sur l'antibiothérapie des pyélonéphrites aiguës du nourrisson et de l'enfant. Médecine et Enfance 2004.
10. Gauthier M., Chevalier I., Sterescu A., et al. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. Pediatrics 2004, 114:e469-e476.
11. Hoberman A., Wald E.R., Hickey R.W., et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999, 104(1Pt1):79-86.
12. Neuhaus T.J., Berger C., Buechner K., et al. Randomised trial of oral versus sequential intravenous/oral cephalosporins in children with pyelonephritis. Eur J Pediatr 2008, 167:1037-1047.
13. Bocquet N., Sergent Alaoui A., Jais J.P., et al. Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children. Pediatrics 2012, 129:e269-e275.
14. Montini G., Toffolo A., Zucchetta P., et al. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial. BMJ 2007, 335:386.
15. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamaseproducing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 3:159-166.
16. Pitout J.D. Infections with extended-spectrum beta-lactamaseproducing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-333.
17. Rodriguez-Bano J., Navarro M.D., Retamar P., et al. Beta-lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012, 54:167-174.
18. Paterson D.L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000, 6:460-463.
19. Kang C.I., Kim S.H., Park W.B., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581.
20. Durrmeyer X., Cohen R. [Pediatric use of carbapenems]. Arch Pediatr 2010, 17(Suppl 4):S163-S170.
21. Overturf G.D. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J 2010, 29:68-70.
22. Dalgic N., Sancar M., Bayraktar B., et al. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis 2011, 43:339-343.
23. Kritsotakis E.I., Tsioutis C., Roumbelaki M., et al. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 2011, 66:1383-1391.
24. Hsueh P.R., Hoban D.J., Carmeli Y., et al. Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect 2011, 63:114-123.
25. Pallett A., Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010, 65(Suppl 3):iii25-iii33.
26. Verboven M., Lauwers S., Pintens H. Temocillin in the treatment of pyelonephritis in children. Drugs Exp Clin Res 1987, 13:171-173.
27. Balakrishnan I., Awad-El-Kariem F.M., Aali A., et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011, 66:2628-2631.
28. Livermore D.M., Tulkens P.M. Temocillin revived. J Antimicrob Chemother 2009, 63:243-245.
29. Giamarellou H. beta-Lactams without a suicide inhibitor. Clin Microbiol Infect 2008, 14(Suppl 1):194-197.
30. Feldman W.E., Moffitt S., Sprow N. Clinical and pharmacokinetic evaluation of parental cefoxitin in infants and children. Antimicrob Agents Chemother 1980, 17:669-674.
31. Bradley J.S., Dudley M.N., Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003, 22:982-992. quiz 93-5.
32. Frimodt-Moller N. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002, 19:546-553.
33. Boyer M., Bignon A., Dessein R., et al. [Cefoxitin and ESBL]. Med Mal Infect 2012, 42:126-128.
34. Bradford P.A., Urban C., Mariano N., et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997, 41:563-569.
35. Pangon B., Bizet C., Bure A., et al. In vivo selection of a cephamycinresistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis 1989, 159:1005-1006.
36. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
37. Yang K., Guglielmo B.J. Diagnosis and treatment of extendedspectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother 2007, 41:1427-1435.
38. Livermore D.M., Hope R., Mushtaq S., et al. Orthodox and unorthodox clavulanate combinations against extended-spectrum beta-lactamase producers. Clin Microbiol Infect 2008, 14(Suppl 1):189-193.
39. Paterson D.L., Ko W.C., Von Gottberg A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum betalactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212.
40. Chopra T., Marchaim D., Veltman J., et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012, 56:3936-3942.
41. Paterson D.L. Treatment of ESBL producers. Enferm Infecc Microbiol Clin 2007, 25(Suppl 2):60-63.
42. Peterson L.R. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 2008, 14(Suppl 1):181-184.
43. Tumbarello M., Spanu T., Sanguinetti M., et al. Bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006, 50:498-504.
44. Gavin P.J., Suseno M.T., Thomson R.B., et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006, 50:2244-2247.
45. Bingen E., Bidet P., Birgy A., et al. In vitro interaction between cefixime and amoxicillin-clavulanate against extented-spectrumbeta-lactamase-producing Escherichia coli causing urinary tract infection. J Clin Microbiol 2012, 50:2540-2541.
46. Madhi F, Bingen E, Biscardi S, et al. Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. Pediatr Infect Dis 2012; in press.
47. Garau J. Other antimicrobials of interest in the era of extendedspectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008, 14(Suppl 1):198-202.
48. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.